Advanced

The α2β1 binding domain of chondroadherin inhibits breast cancer-induced bone metastases and impairs primary tumour growth: A preclinical study.

Rucci, Nadia; Capulli, Mattia; Olstad, Ole K; Önnerfjord, Patrik LU ; Tillgren, Viveka LU ; Gautvik, Kaare M; Heinegård, Dick LU and Teti, Anna (2015) In Cancer Letters 358(1). p.67-75
Abstract
cyclicCHAD is a peptide representing the α2β1 integrin binding sequence of the matrix protein chondroadherin (CHAD), which in our hands proved effective at counteracting bone loss in ovariectomised mice by inhibiting osteoclastogenesis. Given that bone metastases are characterised by exacerbated osteoclast activity as well, we tested this therapy in mice intracardiacally injected with the osteotropic human breast cancer cell line MDA-MB-231. Treatment with cyclicCHAD significantly decreased cachexia and incidence of bone metastases, and induced a trend of reduction of visceral metastasis volume, while in orthotopically injected mice cyclicCHAD reduced tumour volume. In vitro studies showed its ability to impair tumour cell motility and... (More)
cyclicCHAD is a peptide representing the α2β1 integrin binding sequence of the matrix protein chondroadherin (CHAD), which in our hands proved effective at counteracting bone loss in ovariectomised mice by inhibiting osteoclastogenesis. Given that bone metastases are characterised by exacerbated osteoclast activity as well, we tested this therapy in mice intracardiacally injected with the osteotropic human breast cancer cell line MDA-MB-231. Treatment with cyclicCHAD significantly decreased cachexia and incidence of bone metastases, and induced a trend of reduction of visceral metastasis volume, while in orthotopically injected mice cyclicCHAD reduced tumour volume. In vitro studies showed its ability to impair tumour cell motility and invasion, suggesting a direct effect not only on osteoclasts but also on the tumour cell phenotype. Interestingly, when administered together with a suboptimal, poorly effective, dose of doxorubicin (DXR), cyclicCHAD improved survival and reduced visceral metastases volume to a level similar to that of the optimal dose of DXR alone. Taken together, these preclinical data suggest that cyclicCHAD is a new inhibitor of bone metastases, with an appreciable direct effect also on tumour growth and a synergistic activity in combination with low dose chemotherapy, underscoring an important translational impact. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Letters
volume
358
issue
1
pages
67 - 75
publisher
Elsevier
external identifiers
  • pmid:25529009
  • wos:000349507300009
  • scopus:84921390231
ISSN
1872-7980
DOI
10.1016/j.canlet.2014.12.032
language
English
LU publication?
yes
id
a433bf03-c42c-4189-b6a5-59e6e253ed67 (old id 4905829)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25529009?dopt=Abstract
date added to LUP
2015-01-07 14:40:56
date last changed
2017-07-02 03:01:58
@article{a433bf03-c42c-4189-b6a5-59e6e253ed67,
  abstract     = {cyclicCHAD is a peptide representing the α2β1 integrin binding sequence of the matrix protein chondroadherin (CHAD), which in our hands proved effective at counteracting bone loss in ovariectomised mice by inhibiting osteoclastogenesis. Given that bone metastases are characterised by exacerbated osteoclast activity as well, we tested this therapy in mice intracardiacally injected with the osteotropic human breast cancer cell line MDA-MB-231. Treatment with cyclicCHAD significantly decreased cachexia and incidence of bone metastases, and induced a trend of reduction of visceral metastasis volume, while in orthotopically injected mice cyclicCHAD reduced tumour volume. In vitro studies showed its ability to impair tumour cell motility and invasion, suggesting a direct effect not only on osteoclasts but also on the tumour cell phenotype. Interestingly, when administered together with a suboptimal, poorly effective, dose of doxorubicin (DXR), cyclicCHAD improved survival and reduced visceral metastases volume to a level similar to that of the optimal dose of DXR alone. Taken together, these preclinical data suggest that cyclicCHAD is a new inhibitor of bone metastases, with an appreciable direct effect also on tumour growth and a synergistic activity in combination with low dose chemotherapy, underscoring an important translational impact.},
  author       = {Rucci, Nadia and Capulli, Mattia and Olstad, Ole K and Önnerfjord, Patrik and Tillgren, Viveka and Gautvik, Kaare M and Heinegård, Dick and Teti, Anna},
  issn         = {1872-7980},
  language     = {eng},
  number       = {1},
  pages        = {67--75},
  publisher    = {Elsevier},
  series       = {Cancer Letters},
  title        = {The α2β1 binding domain of chondroadherin inhibits breast cancer-induced bone metastases and impairs primary tumour growth: A preclinical study.},
  url          = {http://dx.doi.org/10.1016/j.canlet.2014.12.032},
  volume       = {358},
  year         = {2015},
}